Titan Hopes To Tap Into Niche Drug Addiction Market With Six-Month Implant
This article was originally published in The Pink Sheet Daily
Executive Summary
Titan says compliance and abuse-resistance will hook payers on new long-acting formulations vs. low-cost generics.
You may also be interested in...
Has Aldea Hit On A Sober Approach To Alcohol-Intoxication Therapy?
Acute alcohol intoxication is an unmet medical need that can be both lethal and a cost drain for the health care system, Aldea says. It plans to develop its lead candidate, an ALDH-2 activator, for the rare genetic disorder Fanconi anemia as well.
Bioavailability Key In Naloxone Studies, FDA Official Says
FDA provides a “road map” for potential sponsors of nonclinical and clinical trials of the opioid overdose treatment.
Can Alkermes' Vivitrol Live Up To Commercial Potential In Opioid Dependence?
Company does not plan to compete against market-leading Suboxone, and will initially target the newly addicted, such as young adults, and certain professionals who can't take available treatments.